Concomitant Use of Antibiotics and Immune Checkpoint Inhibitors in Patients With Solid Neoplasms: Retrospective Data From Real-World Settings (Record no. 84667)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02975nab a22002777a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 200713b2020 xxu||||| |||| 00| 0 eng d |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Kapoor A |
| 245 ## - TITLE STATEMENT | |
| Title | Concomitant Use of Antibiotics and Immune Checkpoint Inhibitors in Patients With Solid Neoplasms: Retrospective Data From Real-World Settings |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
| Date of publication, distribution, etc | 2020 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc | Abstract Background: The use of antibiotics is known to alter the gut microbiome and it is hypothesised that the use of antibiotics may also alter the response to immune checkpoint inhibitors (ICI). As data is limited from real-world settings, we performed a retrospective audit of patients who received ICI along with concomitant antibiotics. Patients and methods: This study is a retrospective audit of a prospectively collected the database of patients who received ICI for advanced solid tumours in any line between August 2015 and November 2018 at Tata Memorial Hospital, Mumbai, India. Antibiotic use was recorded from 2 weeks before the start of ICI and concomitantly with ICI. All statistical calculations were performed using Statistical Package for the Social Sciences (SPSS) statistical software for windows version 20.0. Results: A total of 155 patients were identified as having received ICI during the study period, out of which 70 (44%) patients received antibiotics. Median PFS in patients who received antibiotics was 1.7 months (95% CI: 1.1-2.3) as against 3.6 months (95% CI: 2.3-4.8) for patients who did not receive antibiotics (p = 0.912). Median OS in the patients who received antibiotics was 3.9 months (95% CI: 1.8-11.4) as compared to 9.2 months (95% CI: 4.2-12.3) who did not receive antibiotics p = 0.053 (HR = 1.023; 95% CI: 1.00-1.04). Among the patients who received antibiotics, median OS for patients who received ≤10 days of antibiotics was 8.8 months (95% CI: 4.2-11.2) while for patients receiving >10 days of antibiotics, it was 2.8 months (95% CI: 1.2-4.4), p = 0.025 (HR = 2.0, 95% CI: 1.1-3.7). Thirty-three (21.2% of total) patients received antibiotics during the window of 2 weeks before the start of ICI to 2 months of starting ICI. Median OS in the patients who received antibiotics in this window was 2.8 months (95% CI: 1.2-4.5) as compared to 9.2 months (95% CI: 5.2-13.1) who did not receive antibiotics p = 0.008 (HR = 1.8; 95%CI: 1.2-3.0). Conclusions: This study shows that the judicious use of antibiotics is required in patients on ICI or scheduled to be started on ICI. |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Antibiotics |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Immune checkpoint inhibitor |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Real-world data |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Survival |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Noronha V |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Patil VM |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Joshi A |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Menon N |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mahajan A |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Janu A |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Prabhash K |
| 773 ## - HOST ITEM ENTRY | |
| Main entry heading | Ecancermedicalscience |
| Place, publisher, and date of publication | Bristol : Ecancer, 2020 |
| Relationship information | Vol. 14, AR.no.1038. |
| International Standard Serial Number | 1754-6605 |
| 906 ## - LOCAL DATA ELEMENT F, LDF (RLIN) | |
| Dept | Medical Oncology |
| Corporate name | TMC |
| PMID | 32565891 |
| Article Type | Journal Article |
| Country type | International |
| Added Entry | TMH - HBNI |
| First Author | TMH - HBNI |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Item type | Articles |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Permanent location | Current location | Date acquired | Barcode | Date last seen | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tata Memorial Hospital | Tata Memorial Hospital | 2020-07-13 | AR20108 | 2020-07-13 | Articles |